katia Mareschi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8564467/publications.pdf

Version: 2024-02-01

45	3,281	236912	254170
papers	citations	25 h-index	43 g-index

47	47	47	4345
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Novel Xeno-Free Method to Isolate Human Endometrial Mesenchymal Stromal Cells (E-MSCs) in Good Manufacturing Practice (GMP) Conditions. International Journal of Molecular Sciences, 2022, 23, 1931.	4.1	0
2	HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis. Transplantology, 2022, 3, 51-67.	0.6	0
3	A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions. International Journal of Molecular Sciences, 2022, 23, 3234.	4.1	6
4	A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions Preserves the Chemical Characteristics and Biological Activity of Lyo-Secretome Isolated by Ultrafiltration. International Journal of Molecular Sciences, 2022, 23, 4318.	4.1	3
5	Precision Medicine in Osteosarcoma: MATCH Trial and Beyond. Cells, 2021, 10, 281.	4.1	5
6	Genetic and Epigenetic Characterization of a Discordant KMT2A/AFF1-Rearranged Infant Monozygotic Twin Pair. International Journal of Molecular Sciences, 2021, 22, 9740.	4.1	1
7	Organotypic spinal cord cultures: An in vitro 3D model to preliminary screen treatments for spinal muscular atrophy. European Journal of Histochemistry, 2021, 65, .	1.5	3
8	Inactivated Platelet Lysate Supports the Proliferation and Immunomodulant Characteristics of Mesenchymal Stromal Cells in GMP Culture Conditions. Biomedicines, 2020, 8, 220.	3.2	4
9	Cytokine-Induced Killer (CIK) Cells, In Vitro Expanded under Good Manufacturing Process (GMP) Conditions, Remain Stable over Time after Cryopreservation. Pharmaceuticals, 2020, 13, 93.	3.8	13
10	Human endogenous retrovirus, HERV-P and HERV-R in pediatricÂleukemia patients. Journal of Hematopathology, 2019, 12, 51-56.	0.4	2
11	Human Endogenous Retrovirus-H and K Expression in Human Mesenchymal Stem Cells as Potential Markers of Stemness. Intervirology, 2019, 62, 9-14.	2.8	11
12	In Vitro Mesenchymal Progenitor Cell Expansion is a Predictor of Transplant-related Mortality and acute GvHD III-IV After Bone Marrow Transplantation in Univariate Analysis: A Large Single-Center Experience. Journal of Pediatric Hematology/Oncology, 2019, 41, 42-46.	0.6	4
13	Analysis of Mesenchymal Stromal Cell Engraftment After Allogeneic HSCT in Pediatric Patients: A Large Multicenter Study. Journal of Pediatric Hematology/Oncology, 2018, 40, e486-e489.	0.6	2
14	Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity. Journal of Translational Medicine, 2018, 16, 237.	4.4	8
15	A novel TaqMAMA assay for allelic discrimination of TLR9 rs352140 polymorphism. Journal of Virological Methods, 2017, 243, 25-30.	2.1	6
16	Expression of the pol gene of human endogenous retroviruses HERV-K and -W in leukemia patients. Archives of Virology, 2017, 162, 3639-3644.	2.1	29
17	Development of a Low-Cost Stem-Loop Real-Time Quantification PCR Technique for EBV miRNA Expression Analysis. Molecular Biotechnology, 2016, 58, 540-550.	2.4	3
18	Immunoregulatory effects on T lymphocytes by human mesenchymal stromal cells isolated from bone marrow, amniotic fluid, and placenta. Experimental Hematology, 2016, 44, 138-150.e1.	0.4	71

#	ARTICLE	IF	CITATIONS
19	CMV induces HERV-K and HERV-W expression in kidney transplant recipients. Journal of Clinical Virology, 2015, 68, 28-31.	3.1	47
20	H3K4me1 marks DNA regions hypomethylated during aging in human stem and differentiated cells. Genome Research, 2015, 25, 27-40.	5.5	119
21	Inactivated human platelet lysate with psoralen: a new perspective forÂmesenchymal stromal cell production in Good Manufacturing Practice conditions. Cytotherapy, 2014, 16, 750-763.	0.7	55
22	Human mesenchymal stromal cell transplantation modulates neuroinflammatory milieu in a mouse model of amyotrophic lateralÂsclerosis. Cytotherapy, 2014, 16, 1059-1072.	0.7	79
23	Validation of analytical methods in compliance with good manufacturing practice: a practical approach. Journal of Translational Medicine, 2013, 11, 197.	4.4	23
24	Multipotent Mesenchymal Stromal Stem Cell Expansion by Plating Whole Bone Marrow at a Low Cellular Density: A More Advantageous Method for Clinical Use. Stem Cells International, 2012, 2012, 1-10.	2.5	63
25	Validation of analytical methods in GMP: the disposable Fast Read 102Â® device, an alternative practical approach for cell counting. Journal of Translational Medicine, 2012, 10, 112.	4.4	27
26	Myogenic Potential of Whole Bone Marrow Mesenchymal Stem Cells In Vitro and In Vivo for Usage in Urinary Incontinence. PLoS ONE, 2012, 7, e45538.	2.5	40
27	The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors. Journal of Bone and Mineral Research, 2012, 27, 1322-1334.	2.8	27
28	Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. Cytotherapy, 2012, 14, 56-60.	0.7	181
29	Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells. Journal of Hepatology, 2011, 54, 964-974.	3.7	109
30	Dissection of the Biphasic Nature of Hypoxia-Induced Motogenic Action in Bone Marrow-Derived Human Mesenchymal Stem Cells. Stem Cells, 2011, 29, 952-963.	3.2	51
31	Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial. Experimental Neurology, 2010, 223, 229-237.	4.1	333
32	Mesenchymal stem cells for ALS patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 123-124.	2.1	16
33	Stem cells in amyotrophic lateral sclerosis: state of the art. Expert Opinion on Biological Therapy, 2009, 9, 1245-1258.	3.1	16
34	Multipotent mesenchymal stem cells from amniotic fluid originate neural precursors with functional voltage-gated sodium channels. Cytotherapy, 2009, 11, 534-547.	0.7	53
35	Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease, 2008, 31, 395-405.	4.4	269
36	Stem cell treatment in Amyotrophic Lateral Sclerosis. Journal of the Neurological Sciences, 2008, 265, 78-83.	0.6	205

#	ARTICLE	IF	CITATIONS
37	Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut, 2008, 57, 223-231.	12.1	248
38	Bone Marrow Mesenchymal Stem Cells from Healthy Donors and Sporadic Amyotrophic Lateral Sclerosis Patients. Cell Transplantation, 2008, 17, 255-266.	2.5	75
39	Neural differentiation of human mesenchymal stem cells: evidence for expression of neural markers and eag K+ channel types. Experimental Hematology, 2006, 34, 1563-1572.	0.4	134
40	Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. Journal of Cellular Biochemistry, 2006, 97, 744-754.	2.6	289
41	Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Neurological Research, 2006, 28, 523-526.	1.3	169
42	Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 158-161.	1.2	216
43	Association Between Elevated Prolactin Levels and Circulating Erythroid Precursors in Dialyzed Patients. Proceedings of the Society for Experimental Biology and Medicine, 2000, 223, 367-371.	1.8	13
44	Tumor-Associated Transforming Growth Factor-Î² and Interleukin-10 Contribute to a Systemic Th2 Immune Phenotype in Pancreatic Carcinoma Patients. American Journal of Pathology, 1999, 155, 537-547.	3.8	208
45	Bone Marrow Stroma-Derived Prolactin Is Involved in Basal and Platelet-Activating Factorâ€“Stimulated In Vitro Erythropoiesis. Blood, 1997, 90, 21-27.	1.4	45